Innate Pharma

[And its gone!]

BRIEF-Innate Pharma Nine-Months Revenue Down At 33.6 Million Euros
07:08 (17/11) - Bron: Reuters
Nov 17 (Reuters) - INNATE PHARMA SA :
* INNATE PHARMA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
AND
BUSINESS UPDATE
* MONALIZUMAB PHASE 3 STUDY INITIATED, TRIGGERING $50
MILLION
MILESTONE PAYMENT
* LACUTAMAB GRANTED PRIME DESIGNATION IN SÉZARY SYNDROME BY
EUROPEAN MEDICINES AGENCY
* CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY
AMOUNTED
TO EUR 163.6 MILLION AS OF SEPTEMBER 30, 2020
* REVENUES FOR FIRST NINE-MONTHS OF 2020 AMOUNTED TO EUR
33.6
MILLION, COMPARED TO EUR 65.4 MILLION FOR SAME PERIOD IN 2019

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))

163.6 + 50= Cash

[And its gone!]

BRIEF-Innate Pharma To Present Additional Efficacy Data For Monalizumab In Combination With Cetuximab
14:31 (03/12) - Bron: Reuters
Dec 3 (Reuters) - Innate Pharma SA :
* REG- INNATE PHARMA TO PRESENT ADDITIONAL EFFICACY DATA FOR
MONALIZUMAB IN COMBINATION WITH CETUXIMAB IN HEAD AND NECK
CANCER AT THE ESMO IMMUNO-ONCOLOGY VIRTUAL CONGRESS
* PHASE 2 EXPANSION COHORT DATA SUPPORTS ONGOING PHASE 3
TRIAL
* MONALIZUMAB IS A POTENTIALLY FIRST-IN-CLASS IMMUNE
CHECKPOINT
INHIBITOR TARGETING NKG2A RECEPTORS EXPRESSED ON TUMOR
INFILTRATING CYTOTOXIC CD8(+) T CELLS AND NK CELLS

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

[And its gone!]

BUZZ-Innate Pharma: Dropped cancer treatment sinks shares
10:12 (11/12) - Bron: Reuters
** Shares in France-based drugmaker Innate Pharma
sink 17% - on track for their worst day in over three months -
after the company drops commercialisation plans for leukemia
treatment Lumoxiti
** Innate says its will return Lumoxiti's U.S. and EU
commercialisation rights to AstraZeneca , with full
transition planned for 2021
** The CEO says the firm determined there was "low strategic
value" in keeping the drug in its portfolio due to
lower-than-anticipated product sales, compounded by the pandemic
** Portzamparc says this is "very surprising and
disappointing news, which shows that Innate is not yet ready to
take on commercial responsibilities"
** The stock is trading at the bottom of Euronext's Next 150
index , as Friday's losses wipe 70.8 million euros
($85.82 million) off its market value

-18% topaandeel dit!

[Ivel]

BUZZ-Innate Pharma: Dropped cancer treatment sinks shares
10:12 (11/12) - Bron: Reuters
** Shares in France-based drugmaker Innate Pharma
sink 17% - on track for their worst day in over three months -
after the company drops commercialisation plans for leukemia
treatment Lumoxiti
** Innate says its will return Lumoxiti's U.S. and EU
commercialisation rights to AstraZeneca , with full
transition planned for 2021
** The CEO says the firm determined there was "low strategic
value" in keeping the drug in its portfolio due to
lower-than-anticipated product sales, compounded by the pandemic
** Portzamparc says this is "very surprising and
disappointing news, which shows that Innate is not yet ready to
take on commercial responsibilities"
** The stock is trading at the bottom of Euronext's Next 150
index , as Friday's losses wipe 70.8 million euros
($85.82 million) off its market value

-18% topaandeel dit!

Ik hoop dat ze rap overgenomen worden.
Onaanvaardbaar dit.

[And its gone!]

Voor 7 euro mogen ze de hele boite hebben. Hoe rapper hoe beter.
Om 14u uitleg van de CEO, zullen erna nog eens 20% zakken, wat een sukkelaar

[NewB76]

Anderzijds is een verkoop-organisatie opzetten in de US niet eenvoudig . Astra-Zeneca heeft dit reeds , en kan een niche product toevoegen aan haar portfolio .

[gigagoeroe]

Ik vind dit precies nu ook niet zo een drama.
Maar die communicatie is zo dramatsich slecht, dat je bijna begint te denken dat ze het met opzet doen.
Voor de opportunisten die denken dat rond 3€ kopen, binnen de 6 maanden tot rond 4,5€ verkopen leidt.
Niet eens zolang moeten wachten deze keer.

[Ivel]

Ik vind dit precies nu ook niet zo een drama.
Maar die communicatie is zo dramatsich slecht, dat je bijna begint te denken dat ze het met opzet doen.
Voor de opportunisten die denken dat rond 3€ kopen, binnen de 6 maanden tot rond 4,5€ verkopen leidt.
Niet eens zolang moeten wachten deze keer.

Waarom zou het naar 4.5€ gaan?
Er is +- 20% van de pipeline geschrapt.

[NewB76]

Beslissing EMEA CHMP (7 tot 10 december2020 )
The Committee recommended granting a marketing authorisation under exceptional circumstances for Lumoxiti* (moxetumomab pasudotox) for the treatment of relapsed or refractory hairy cell leukaemia, a cancer of a type of white blood cell called B-lymphocytes.( via Astra-Zeneca volgens documentatie )

[NewB76]

En wat koopt Astra-Zeneca: Alexion een weesgeneesmiddelenbedrijf in de US !